Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

KORE vs BBLG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KORE Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 4–4 Matrix Metrics)

KORE Overall Winner 6-Pillar Tally: KORE 5 – 1 BBLG Matrix Metrics: KORE 4 – 4 BBLG

As of Nov 20, 2026, KORE Group Holdings, Inc. (KORE) is the stronger overall head-to-head candidate over Bone Biologics Corp (BBLG) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). KORE carries a Unified Composite Score of 55.3/100 (HOLD) at $9.25 (N/M Forward P/E, -6.2% operating margin), whereas BBLG carries 44.8/100 (HOLD) at $0.27 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: KORE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 50.5); meanwhile BBLG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KORE vs BBLG
KORE NYSE Head-to-Head Winner
KORE Group Holdings, Inc.
Communications Services, Nec
$9.25
-0.11% 1D
Market Cap $163.0M
TTM Revenue $280M
Forward P/E N/M
Beta / 30D Vol -0.15β · 29% Vol
Unified Composite Score
55.3 / 100 HOLD
Tech 40.0 Fund 48.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.6% over 20 days), RSI 51
RSI-14: 50.5 · SMA20: $9.27 · SMA50: $9.22
BBLG NASDAQ
Bone Biologics Corp Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.27
-2.4% 1D
Market Cap $932,329
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.97β · 102% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 33.0 Fund 48.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.7%), weak momentum, RSI 31
RSI-14: 30.9 · SMA20: $0.34 · SMA50: $0.42

6-Pillar Scorecard Institutional Category Breakdown (KORE 5 – 1 BBLG)

Columns: Metric · KORE · BBLG
1. Valuation Multiples KORE
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 1.5x N/M
2. Growth & Scale KORE
Revenue Growth (YoY) -8.8% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $280M N/A
Market Cap $163.0M $932,329
3. Profitability & Quality BBLG
Gross Margin 56.5% N/A
Operating Margin -6.2% 0.0%
Net Profit Margin -27.4% 0.0%
Return on Equity (ROE) -336.9% -47.5%
4. Balance Sheet & Cash Flow KORE
Cash Generation (TTM) $11M N/A
Cash Flow Margin 3.9% N/A
Net Cash / Leverage $270M Net Debt $1.76 Book/Sh · -47.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning KORE
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat KORE
OpEx & R&D Intensity 62.7% of Rev ($175M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Telecom Services Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KORE (4) vs BBLG (4)
Institutional Metric KORE BBLG Criterion Row Edge
Market Capitalization
Scale
$163.0M $932,329 Larger Scale KORE
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-8.8% +0.0% Higher Growth BBLG
Operating Margin (TTM)
Profitability
-6.2% 0.0% Higher Margin BBLG
Net Profit Margin
Profitability
-27.4% 0.0% Higher Margin BBLG
Return on Equity (ROE)
Capital Efficiency
-336.9% -47.5% Higher ROE BBLG
52-Week Range Position
Momentum
93% ($2–$10) 0% ($0–$2) Stronger Trend KORE
Beta / 30D Volatility
Risk Regime
-0.15β · 29% Vol 0.97β · 102% Vol Lower Realized Risk KORE
Unified Institutional Score
Composite Signal
55.3 / 100 (HOLD) 44.8 / 100 (HOLD) Higher Composite KORE
Trailing 12M Revenue (USD)
Operating Scale
$280M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
56.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$11M ($270M Net Debt) N/A ($1.76 Book/Sh · -47.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KORE +24.57 pp
KORE: +0.76% · BBLG: -23.81%
3M Horizon KORE +20.62 pp
KORE: +1.2% · BBLG: -19.42%
6M Horizon KORE +121.32 pp
KORE: +88.39% · BBLG: -32.93%
1Y Horizon KORE +146.31 pp
KORE: +117.65% · BBLG: -28.66%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period KORE Revenue BBLG Revenue KORE Op. Margin BBLG Op. Margin Margin Leader
FY2019 $170M $1.07B -7.0% -0.2% BBLG
FY2020 $210M $1.07B -4.5% -0.1% BBLG
FY2021 $250M N/A -6.3% N/A KORE
FY2022 $270M N/A -31.8% N/A KORE
FY2023 $280M N/A -42.9% N/A KORE
FY2024 $290M N/A -35.9% N/A KORE
FY2025 $290M N/A -4.4% N/A KORE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KORE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KORE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BBLG BREAKDOWN
104d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact BBLG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KORE Moat Profile Cyclical / Execution-Driven Positioning
Telecom Services Operator
Competes within the Telecom Services value chain with $163.0M market capitalization and -6.2% operating margin.
OpEx & R&D Reinvestment 62.7% of Rev ($175M)
90D Engineering Disclosures 0 Published
BBLG Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $932,329 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ KORE vs BBLG Key Questions & Quantitative Answers

As of Nov 20, 2026, KORE Group Holdings, Inc. (KORE) is the stronger overall head-to-head candidate over Bone Biologics Corp (BBLG) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). KORE carries a Unified Composite Score of 55.3/100 (HOLD) at $9.25 (N/M Forward P/E, -6.2% operating margin), whereas BBLG carries 44.8/100 (HOLD) at $0.27 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: KORE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 50.5); meanwhile BBLG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KORE leads the Growth & Scale pillar: KORE posts -8.8% YoY revenue growth and +0.0% YoY earnings growth on $280M TTM revenue (56.5% gross margin, -6.2% operating margin), compared with BBLG at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), KORE cumulative revenue shifted +70.6% while BBLG shifted +0.0%. In operating R&D and SG&A reinvestment, KORE deploys 62.7% of Rev ($175M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BBLG.

KORE screens cheaper on headline valuation multiples. KORE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.5x EV/Revenue (3.9% FCF margin), whereas BBLG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KORE (-336.9% ROE) versus BBLG (-47.5% ROE) capital efficiency.

In options market volatility and institutional positioning, KORE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.15β · 29% Vol realized risk). By comparison, BBLG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.97β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.